Elanco Animal Health Incorporated (NYSE:ELAN) Shares Bought by Teza Capital Management LLC

Teza Capital Management LLC grew its stake in Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) by 47.6% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 99,818 shares of the company's stock after acquiring an additional 32,173 shares during the period. Teza Capital Management LLC's holdings in Elanco Animal Health were worth $1,209,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. CoreCap Advisors LLC purchased a new stake in Elanco Animal Health during the fourth quarter worth $29,000. Jones Financial Companies Lllp grew its position in shares of Elanco Animal Health by 95.6% in the 4th quarter. Jones Financial Companies Lllp now owns 4,212 shares of the company's stock worth $51,000 after buying an additional 2,059 shares during the last quarter. SRS Capital Advisors Inc. lifted its position in Elanco Animal Health by 221.2% during the fourth quarter. SRS Capital Advisors Inc. now owns 4,953 shares of the company's stock valued at $60,000 after acquiring an additional 3,411 shares during the last quarter. MRP Capital Investments LLC acquired a new stake in Elanco Animal Health in the fourth quarter valued at approximately $61,000. Finally, Blue Trust Inc. boosted its stake in Elanco Animal Health by 47.7% in the fourth quarter. Blue Trust Inc. now owns 5,862 shares of the company's stock valued at $71,000 after acquiring an additional 1,894 shares in the last quarter. 97.48% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, Director Lawrence Erik Kurzius purchased 10,000 shares of the business's stock in a transaction dated Tuesday, March 11th. The stock was acquired at an average price of $10.20 per share, for a total transaction of $102,000.00. Following the acquisition, the director now directly owns 111,459 shares of the company's stock, valued at approximately $1,136,881.80. This represents a 9.86% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.89% of the stock is currently owned by company insiders.

Elanco Animal Health Stock Performance

NYSE:ELAN traded up $0.06 during midday trading on Thursday, hitting $12.68. The company's stock had a trading volume of 4,875,464 shares, compared to its average volume of 5,064,720. Elanco Animal Health Incorporated has a fifty-two week low of $8.02 and a fifty-two week high of $18.80. The company has a debt-to-equity ratio of 0.66, a current ratio of 2.55 and a quick ratio of 1.31. The firm has a market cap of $6.30 billion, a P/E ratio of 31.70, a P/E/G ratio of 2.50 and a beta of 1.49. The firm's 50 day moving average is $10.26 and its 200-day moving average is $11.45.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last posted its earnings results on Wednesday, May 7th. The company reported $0.37 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.31 by $0.06. The firm had revenue of $1.19 billion during the quarter, compared to analysts' expectations of $1.17 billion. Elanco Animal Health had a net margin of 4.60% and a return on equity of 6.78%. The business's revenue was down 1.0% compared to the same quarter last year. During the same period in the previous year, the business posted $0.34 EPS. Equities analysts anticipate that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

ELAN has been the topic of a number of recent analyst reports. UBS Group reduced their price target on Elanco Animal Health from $18.00 to $17.00 and set a "buy" rating on the stock in a research report on Wednesday, February 26th. Morgan Stanley reduced their target price on Elanco Animal Health from $14.00 to $13.00 and set an "equal weight" rating on the stock in a research report on Wednesday, February 26th. Piper Sandler lowered their price target on Elanco Animal Health from $16.00 to $12.00 and set a "neutral" rating for the company in a report on Thursday, March 6th. Stifel Nicolaus boosted their price target on Elanco Animal Health from $15.00 to $16.00 and gave the stock a "buy" rating in a research note on Monday. Finally, Barclays decreased their price objective on shares of Elanco Animal Health from $20.00 to $19.00 and set an "overweight" rating for the company in a research report on Wednesday, February 26th. Four research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average price target of $15.17.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.